ReviewExtracellular vesicles and circulating nucleic acids2025
Tear-derived extracellular vesicles as diagnostic biomarkers for ocular and neurodegenerative diseases: opportunities and challenges.
Review in Extracellular vesicles and circulating nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Harnessing exosomes in dry eye disease: a triple threat approach.BMC ophthalmology · 2026Pooled it
- Investigation Into the Collection and Isolation Workflows of Extracellular Vesicles From Tears.Journal of extracellular biology · 2026Article
- Oxidative Stress in Diabetic Retinopathy: Pathogenic Mechanisms, Biomarkers and Clinical Implications.Antioxidants (Basel, Switzerland) · 2026Review
- Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Integrated tear proteomics define the molecular blueprint of corneal epithelial repair.Experimental biology and medicine (Maywood, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the prevalence of ocular diseases has increased considerably. However, timely diagnosis and treatment are hampered by the challenge of early detection since symptoms often appear in advanced stages. Emerging research highlights extracellular vesicles (EVs) as potential biomarkers for ocular diseases, with tear-derived EVs offering a minimally invasive source for early diagnosis. Tears play a crucial role in maintaining eye health and reflect the physiological state of the eye; thus, abnormalities in tear composition can provide valuable insight into inflammatory eye diseases. Studies have demonstrated the utility of tear-derived EVs in identifying biomarkers not only for inflammatory eye diseases but also for neurodegenerative disorders, as they carry molecular signatures (including proteins and various RNA species) reflective of their cells of origin. In this review, we discuss the potential of tear-derived EVs as biomarkers for early detection and monitoring of ocular and neurodegenerative diseases and highlight the importance of standardizing tear collection and EV isolation protocols to ensure reproducibility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.